Literature DB >> 26067823

IL1RAP expression as a measure of leukemic stem cell burden at diagnosis of chronic myeloid leukemia predicts therapy outcome.

N Landberg1, N Hansen1, M Askmyr1, H Ågerstam1, C Lassen1, M Rissler1, H Hjorth-Hansen2,3, S Mustjoki4, M Järås1, J Richter5, T Fioretos1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26067823     DOI： 10.1038/leu.2015.135

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein.

Authors:  Marcus Järås; Petra Johnels; Nils Hansen; Helena Agerstam; Panagiotis Tsapogas; Marianne Rissler; Carin Lassen; Tor Olofsson; Ole Weis Bjerrum; Johan Richter; Thoas Fioretos
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-30       Impact factor: 11.205

Review 2.  The development of imatinib as a therapeutic agent for chronic myeloid leukemia.

Authors:  Michael Deininger; Elisabeth Buchdunger; Brian J Druker
Journal:  Blood       Date:  2004-12-23       Impact factor: 22.113

3.  Detection of molecular targets on the surface of CD34+/CD38-- stem cells in various myeloid malignancies.

Authors:  Stefan Florian; Karoline Sonneck; Alexander W Hauswirth; Maria-Theresa Krauth; Gerit-Holger Schernthaner; Wolfgang R Sperr; Peter Valent
Journal:  Leuk Lymphoma       Date:  2006-02

4.  Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML).

Authors:  B Hanfstein; M C Müller; R Hehlmann; P Erben; M Lauseker; A Fabarius; S Schnittger; C Haferlach; G Göhring; U Proetel; H-J Kolb; S W Krause; W-K Hofmann; J Schubert; H Einsele; J Dengler; M Hänel; C Falge; L Kanz; A Neubauer; M Kneba; F Stegelmann; M Pfreundschuh; C F Waller; S Branford; T P Hughes; K Spiekermann; G M Baerlocher; M Pfirrmann; J Hasford; S Saußele; A Hochhaus
Journal:  Leukemia       Date:  2012-03-26       Impact factor: 11.528

Review 5.  Insights into the stem cells of chronic myeloid leukemia.

Authors:  I Sloma; X Jiang; A C Eaves; C J Eaves
Journal:  Leukemia       Date:  2010-09-23       Impact factor: 11.528

6.  Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib.

Authors:  J J W M Janssen; W Deenik; K G M Smolders; B J van Kuijk; W Pouwels; A Kelder; J J Cornelissen; G J Schuurhuis; G J Ossenkoppele
Journal:  Leukemia       Date:  2011-12-09       Impact factor: 11.528

7.  Impact of malignant stem cell burden on therapy outcome in newly diagnosed chronic myeloid leukemia patients.

Authors:  S Mustjoki; J Richter; G Barbany; H Ehrencrona; T Fioretos; T Gedde-Dahl; B T Gjertsen; R Hovland; S Hernesniemi; D Josefsen; P Koskenvesa; I Dybedal; B Markevärn; T Olofsson; U Olsson-Strömberg; K Rapakko; S Thunberg; L Stenke; B Simonsson; K Porkka; H Hjorth-Hansen
Journal:  Leukemia       Date:  2013-01-18       Impact factor: 11.528

8.  Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells.

Authors:  Eva Nievergall; Hayley S Ramshaw; Agnes S M Yong; Mark Biondo; Samantha J Busfield; Gino Vairo; Angel F Lopez; Timothy P Hughes; Deborah L White; Devendra K Hiwase
Journal:  Blood       Date:  2013-12-20       Impact factor: 22.113

Review 9.  Deep molecular response in chronic myeloid leukemia: the new goal of therapy?

Authors:  François-Xavier Mahon; Gabriel Etienne
Journal:  Clin Cancer Res       Date:  2013-10-28       Impact factor: 12.531

Review 10.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.

Authors:  Michele Baccarani; Michael W Deininger; Gianantonio Rosti; Andreas Hochhaus; Simona Soverini; Jane F Apperley; Francisco Cervantes; Richard E Clark; Jorge E Cortes; François Guilhot; Henrik Hjorth-Hansen; Timothy P Hughes; Hagop M Kantarjian; Dong-Wook Kim; Richard A Larson; Jeffrey H Lipton; François-Xavier Mahon; Giovanni Martinelli; Jiri Mayer; Martin C Müller; Dietger Niederwieser; Fabrizio Pane; Jerald P Radich; Philippe Rousselot; Giuseppe Saglio; Susanne Saußele; Charles Schiffer; Richard Silver; Bengt Simonsson; Juan-Luis Steegmann; John M Goldman; Rüdiger Hehlmann
Journal:  Blood       Date:  2013-06-26       Impact factor: 22.113
View more
  17 in total

1.  Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML.

Authors:  Rebecca Warfvinge; Linda Geironson; Mikael N E Sommarin; Stefan Lang; Christine Karlsson; Teona Roschupkina; Leif Stenke; Jesper Stentoft; Ulla Olsson-Strömberg; Henrik Hjorth-Hansen; Satu Mustjoki; Shamit Soneji; Johan Richter; Göran Karlsson
Journal:  Blood       Date:  2017-01-25       Impact factor: 22.113

2.  First-in-human phase 1 dose-escalation study of CAN04, a first-in-class interleukin-1 receptor accessory protein (IL1RAP) antibody in patients with solid tumours.

Authors:  Debbie Robbrecht; Christiane Jungels; Morten Mau Sorensen; Iben Spanggaard; Ferry Eskens; Signe Ø Fretland; Tormod Kyrre Guren; Philippe Aftimos; David Liberg; Christer Svedman; Lars Thorsson; Neeltje Steeghs; Ahmad Awada
Journal:  Br J Cancer       Date:  2021-12-13       Impact factor: 9.075

Review 3.  Targeting Leukemia Stem Cells in the Bone Marrow Niche.

Authors:  Sarah K Tasian; Martin Bornhäuser; Sergio Rutella
Journal:  Biomedicines       Date:  2018-02-21

4.  CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting.

Authors:  Niklas Landberg; Sofia von Palffy; Maria Askmyr; Henrik Lilljebjörn; Carl Sandén; Marianne Rissler; Satu Mustjoki; Henrik Hjorth-Hansen; Johan Richter; Helena Ågerstam; Marcus Järås; Thoas Fioretos
Journal:  Haematologica       Date:  2017-12-28       Impact factor: 9.941

5.  SRSF10-mediated IL1RAP alternative splicing regulates cervical cancer oncogenesis via mIL1RAP-NF-κB-CD47 axis.

Authors:  Fei Liu; Miao Dai; Qinyang Xu; Xiaolu Zhu; Yang Zhou; Shuheng Jiang; Yahui Wang; Zhihong Ai; Li Ma; Yanli Zhang; Lipeng Hu; Qin Yang; Jun Li; Shujie Zhao; Zhigang Zhang; Yincheng Teng
Journal:  Oncogene       Date:  2018-02-12       Impact factor: 9.867

6.  Quantitative assessment of the CD26+ leukemic stem cell compartment in chronic myeloid leukemia: patient-subgroups, prognostic impact, and technical aspects.

Authors:  Martin Culen; Marek Borsky; Veronika Nemethova; Filip Razga; Jiri Smejkal; Tomas Jurcek; Dana Dvorakova; Daniela Zackova; Barbora Weinbergerova; Lukas Semerad; Irina Sadovnik; Gregor Eisenwort; Harald Herrmann; Peter Valent; Jiri Mayer; Zdenek Racil
Journal:  Oncotarget       Date:  2016-05-31

7.  A new monoclonal antibody detects downregulation of protein tyrosine phosphatase receptor type γ in chronic myeloid leukemia patients.

Authors:  Marzia Vezzalini; Andrea Mafficini; Luisa Tomasello; Erika Lorenzetto; Elisabetta Moratti; Zeno Fiorini; Tessa L Holyoake; Francesca Pellicano; Mauro Krampera; Cristina Tecchio; Mohamed Yassin; Nader Al-Dewik; Mohamed A Ismail; Ali Al Sayab; Maria Monne; Claudio Sorio
Journal:  J Hematol Oncol       Date:  2017-06-21       Impact factor: 17.388

Review 8.  Therapeutic Antibodies for Myeloid Neoplasms-Current Developments and Future Directions.

Authors:  Christian M Schürch
Journal:  Front Oncol       Date:  2018-05-18       Impact factor: 6.244

9.  IL1RAP potentiates multiple oncogenic signaling pathways in AML.

Authors:  Kelly Mitchell; Laura Barreyro; Tihomira I Todorova; Samuel J Taylor; Iléana Antony-Debré; Swathi-Rao Narayanagari; Luis A Carvajal; Joana Leite; Zubair Piperdi; Gopichand Pendurti; Ioannis Mantzaris; Elisabeth Paietta; Amit Verma; Kira Gritsman; Ulrich Steidl
Journal:  J Exp Med       Date:  2018-05-17       Impact factor: 14.307

10.  Evaluation of the primitive fraction by functional in vitro assays at the RNA and DNA level represents a novel tool for complementing molecular monitoring in chronic myeloid leukemia.

Authors:  María Sol Ruiz; María Belén Sanchez; Leandro Gutiérrez; Daniel Koile; Patricio Yankilevich; Celeste Mosqueira; Santiago Cranco; María Del Rosario Custidiano; Josefina Freitas; Cecilia Foncuberta; Beatriz Moiraghi; Carolina Pavlovsky; Mariel Ana Pérez; Verónica Ventriglia; Julio Sanchez Ávalos; José Mordoh; Irene Larripa; Michele Bianchini
Journal:  Oncotarget       Date:  2018-04-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.